Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models. (July 2016) - Saturno, G.; Lopes, F.; Girotti, M.R.; Niculescu-Duvaz, I.; Niculescu-Duvaz, D.; Zambon, A.; Davies, L.; Johnson, L.; Preece, N.; Viros, A.; Pedersen, M.; McLeary, R.; et al.